Single Status Update
MEKT1 Could Be a Potential New Therapy for Treating Cushing’s Disease
PPAR-γ agonists — agents that activate PPAR-γ — include the medications rosiglitazone and pioglitazone, both of which are used to treat type 2 diabetes. Some studies have shown that rosiglitazone and pioglitazone have an effect on Pomc suppression, which would lead to lower levels of ACTH and help treat patients with Cushing’s disease.
However, the benefits of PPAR-γ agonists in the treatment of Cushing’s disease are still controversial.